Sex‐Dependent Improvement in Survival of Parkinson's Disease Patients
| Autor: | Heli Salminen-Mankonen, Valtteri Kaasinen, Jussi O.T. Sipilä, Samu Kurki, Tomi Kuusimäki, Olli Carpén |
|---|---|
| Přispěvatelé: | HUSLAB, Precision Cancer Pathology, Department of Pathology, Olli Mikael Carpen / Principal Investigator, Research Program in Systems Oncology, Research Programs Unit, University of Helsinki, Helsinki University Hospital Area |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
REHABILITATION medicine.medical_specialty Levodopa PHARMACOKINETICS Parkinson's disease MONOTHERAPY Disease 030105 genetics & heredity CONTROLLED-TRIAL survival 3124 Neurology and psychiatry law.invention 03 medical and health sciences DOUBLE-BLIND 0302 clinical medicine Randomized controlled trial law Internal medicine medicine gender sex SELEGILINE Research Articles Cause of death Pramipexole business.industry LEVODOPA 3112 Neurosciences medicine.disease mortality 3. Good health Pneumonia Neurology RASAGILINE Life expectancy PRAMIPEXOLE Neurology (clinical) DEEP-BRAIN-STIMULATION business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Mov Disord Clin Pract |
| Popis: | Background Advances in the treatment of Parkinson's disease (PD) and changes in general life expectancy may have improved survival in patients with PD. Objective The objective of this study was to investigate recent trends in PD mortality. Methods In total, 1521 patients with PD in local and national registries were followed for 11 years (2006-2016) from diagnosis until exit date or death, and the causes of death were recorded. Results The survival of men with PD improved during the follow-up period, but no change was observed in women (2-year postdiagnosis survival in men, 79.0%-86.3%, P = 0.03; 2-year postdiagnosis survival in women, 82.8%-87.5%, P = 0.42). Pneumonia was the most common immediate cause of death. Discussion The survival of men with PD has improved in Finland without a similar change in women. Because changes in treatment likely affect both sexes similarly, the results may reflect the decreasing sex gap in life expectancy. This phenomenon will likely increase the already high male-to-female prevalence ratio of PD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|